Volume | 123,806 |
|
|||||
News | - | ||||||
Day High | 0.6999 | Low High |
|||||
Day Low | 0.664 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Lucid Diagnostics Inc | LUCD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.6777 | 0.664 | 0.6999 | 0.6831 | 0.6701 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
377 | 123,806 | US$ 0.679886 | US$ 84,174 | - | 0.6301 - 1.85 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:22:00 | 2 | US$ 0.6899 | USD |
Lucid Diagnostics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
30.37M | 44.67M | - | 2.43M | -52.67M | -1.18 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Lucid Diagnostics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LUCD Price Data
Period †| Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.795 | 0.8173 | 0.6301 | 0.7148792 | 206,674 | -0.105 | -13.21% |
1 Month | 0.8825 | 0.95 | 0.6301 | 0.8236592 | 189,377 | -0.1925 | -21.81% |
3 Months | 1.48 | 1.48 | 0.6301 | 1.02 | 182,830 | -0.79 | -53.38% |
6 Months | 1.21 | 1.58 | 0.6301 | 1.10 | 107,208 | -0.52 | -42.98% |
1 Year | 1.46 | 1.85 | 0.6301 | 1.21 | 77,933 | -0.77 | -52.74% |
3 Years | 12.75 | 13.50 | 0.6301 | 3.63 | 119,853 | -12.06 | -94.59% |
5 Years | 12.75 | 13.50 | 0.6301 | 3.63 | 119,853 | -12.06 | -94.59% |
Lucid Diagnostics Description
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. |